Annotation Detail
Information
- Associated Genes
- NF1
- Associated Variants
-
NF1 MUTATION
NF1 MUTATION - Associated Disease
- skin melanoma
- Source Database
- CIViC Evidence
- Description
- Preclinical study of mouse melanoma in-vitro and in-vivo. In-vitro treament of Braf-mutant melanomas were 10-fold more sensitive to vermurafenib (PLX4032) treatment than Braf/Nf1-mutant melanomas. In vivo treatment of mice with Braf/Nf1-mutant allografts showed less sensitivity to vemurafenib (PLX4032) than the MEK inhibitor, PD0325901.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1468
- Gene URL
- https://civic.genome.wustl.edu/links/genes/3867
- Variant URL
- https://civic.genome.wustl.edu/links/variants/587
- Rating
- 2
- Evidence Type
- Predictive
- Disease
- Skin Melanoma
- Evidence Direction
- Supports
- Drug
- Vemurafenib
- Evidence Level
- D
- Clinical Significance
- Resistance
- Pubmed
- 23171796
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Vemurafenib | Resitance or Non-Reponse | true |